A clinical trial to assess a new drug (KPL-716) for prurigo nodularis (PN).
Study completed
About this study
Prurigo nodularis (PN) is a chronic skin disease that characterised by hard, intensely itchy (pruritus) lumps that form on the skin. Currently there are no approved therapies to treat PN.
KPL-716 is a drug made up of a protein known as an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody KPL-716 works by inhibiting certain inflammatory mediators and pathways involved in inflammation and pruritus.
The aim of the Kiniksa study is to assess the safety, efficacy and tolerability of the new drug in reducing pruritus in people with PN.